Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical benefit and harm
dc.contributor.author | Parrish, A. | |
dc.contributor.author | Gray, A. | |
dc.contributor.author | Kredo, T. | |
dc.contributor.author | Maartens, G. | |
dc.contributor.author | Reubenson, G. | |
dc.contributor.author | Cohen, K. | |
dc.contributor.author | De Waal, R. | |
dc.contributor.author | Blockman, M. | |
dc.contributor.author | Nel, J. | |
dc.contributor.author | Rees, H. | |
dc.contributor.department | Cochrane South Africa, South African Medical Research Council | en_US |
dc.date.accessioned | 2020-07-20T09:08:58Z | |
dc.date.available | 2020-07-20T09:08:58Z | |
dc.date.epub | 2020-04-15 | |
dc.date.issued | 2020-04-15 | |
dc.identifier.uri | https://infospace.mrc.ac.za/handle/11288/595270 | |
dc.language.iso | en | en_US |
dc.publisher | South African National Department of Health | en_US |
dc.research.unit | South African Cochrane Centre | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Interleukin‐6 Inhibitor, Tocolizumab, for COVID‐19: evidence review of the clinical benefit and harm | en_US |
dc.type | Other | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Parris A_2020_Iinterleukin-6 inhibitor.pdf
- Size:
- 241.3 KB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: